Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for COVID-19 Treatment in Outpatients Nationwide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of a positive SARS-CoV-2 test and test results received within the previous seven days~* Not currently hospitalized~* Willing and able to receive study drug by mail~* Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone~* No known allergy or other contraindication to macrolides~* Age 18 years or older at the time of enrollment~* No known history of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)~* No recent use of hydroxychloroquine within the past 7 days for participants \>55 years of age~* Not currently taking nelfinavir or warfarin (Coumadin)~* Provision of informed consent~* Not currently pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): 1.2g of oral azithromycin
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).